Syed Ahmed, MD
Psychiatry · Williamsville, NYNPI 1003828526
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,400 of the $38,903 with a category attached, or 70.4%. Johnson & Johnson accounts for 88.6% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2022 at $21,058 and has fallen 94.3% since, to $1,195 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 341 payments — averaging $114.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$34K
- AbbVie$808
- Alkermes, Inc.$446
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$436
- Otsuka America Pharmaceutical, Inc.$401
- Bausch Health US, LLC$377
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$27,40070%
- Travel & lodging$5,39614%
- Food & beverage$6,02815%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 111 | $34,452 |
| AbbVie(2 entities) | 58 | $808 |
| Alkermes, Inc. | 18 | $446 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $436 |
| Otsuka America Pharmaceutical, Inc. | 19 | $401 |
| Bausch Health US, LLC | 20 | $377 |
| Teva Pharmaceuticals USA, Inc. | 12 | $259 |
| Indivior Inc. | 9 | $228 |
| Axsome Therapeutics, Inc. | 9 | $211 |
| Vanda Pharmaceuticals Inc. | 6 | $176 |
| Neurocrine Biosciences, Inc. | 8 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $165 |
| Idorsia Pharmaceuticals US Inc | 6 | $121 |
| Orexo US, Inc. | 4 | $61 |
| Lundbeck LLC | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 7 | $58 |
| Octapharma USA, Inc. | 2 | $46 |
| Fidia Pharma USA Inc. | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| UCB, Inc. | 2 | $33 |
| Pfizer | 2 | $29 |
| Corium, LLC | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Abbott | 1 | $24 |
| Sandoz | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$32,846
How this compares
$38,903 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 41 | $59,467 |
| VraylarCariprazine Hcl | 15 | $21,334 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,144 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 36 | $7,992 |
| Lisdexamfetamine Dimesylate | 19 | $3,903 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 218 | $3,482 |
| Vilazodone Hcl | 20 | $2,548 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 47 | $1,716 |
| Zolpidem Tartrate ErZolpidem Tartrate | 22 | $1,713 |
| Bupropion XlBupropion Hcl | 102 | $1,510 |
| Quetiapine Fumarate | 63 | $1,281 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $1,229 |
| Sertraline Hcl | 98 | $776 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $762 |
| Lorazepam | 101 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $401 | $59,46741 claims |
| AbbVieVraylar | $808 | $21,33415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $165 | $14,14430 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $77698 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Williamsville
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.